The “SEED” Study: The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric and Young Adult Patients with Recurrent or Refractory Brain Tumors

The “SEED” Study: The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric and Young Adult Patients with Recurrent or Refractory Brain Tumors

Background: Pediatric brain tumors are the leading cause of cancer death in children and represent a variety of diseases and molecular subtypes. This study sought to evaluate a rapid immunohistochemistry testing panel to aid in therapy selection at the time of malignant tumor recurrence. Methods: Wi...

Full description

Bibliographic Details
Main Authors: Bonnie L. Cole, Kimberly Starr, Christina M. Lockwood, Sarah E. S. Leary
Format: Article
Language:English
Published: IMR Press 2022-07-01
Series:Frontiers in Bioscience-Landmark
Subjects:
targeted
chemotherapy
pediatric
brain tumor
clinical trial
Online Access:https://www.imrpress.com/journal/FBL/27/7/10.31083/j.fbl2707219

Internet

https://www.imrpress.com/journal/FBL/27/7/10.31083/j.fbl2707219

Similar Items